Registration Dossier

Data platform availability banner - registered substances factsheets

Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.

The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.

Diss Factsheets

Administrative data

Key value for chemical safety assessment

Effects on fertility

Description of key information

Repeated dose toxicity (OECD TG 422): NOAEL = 88 mg/kg bw/day for females and >708 mg/kg bw/day for males (highest dose tested)

Link to relevant study records
Reference
Endpoint:
screening for reproductive / developmental toxicity
Type of information:
experimental study
Adequacy of study:
key study
Study period:
19-12-2016 to 23-02-2017
Reliability:
1 (reliable without restriction)
Rationale for reliability incl. deficiencies:
guideline study
Reason / purpose for cross-reference:
reference to same study
Qualifier:
according to guideline
Guideline:
OECD Guideline 422 (Combined Repeated Dose Toxicity Study with the Reproduction / Developmental Toxicity Screening Test)
Version / remarks:
1996
Deviations:
no
GLP compliance:
yes (incl. QA statement)
Limit test:
no
Specific details on test material used for the study:
STABILITY AND STORAGE CONDITIONS OF TEST MATERIAL
- Storage condition of test material: Ambient temperature, protected from light
- Expiration date of the lot/batch: 31 May 2018
- Purity test date: 9 Aug 2016

TREATMENT OF TEST MATERIAL PRIOR TO TESTING
- Treatment of test material prior to testing: The test item was formulated daily, using powdered diet, by initial preparation of a premix followed by dilution with further quantities of diet and mixing.

FORM AS APPLIED IN THE TEST
Mixed into powdered rodent diet
Species:
rat
Strain:
Sprague-Dawley
Details on species / strain selection:
The Sprague Dawley rat is the species and strain of choice because it is accepted by regulatory authorities, recognized as appropriate for general and reproduction toxicity studies and there is ample experience and background data on this species and strain.
Sex:
male/female
Details on test animals or test system and environmental conditions:
TEST ANIMALS
- Source: Charles River Italia S.p.A., Calco (Lecco), Italy.
- Females (if applicable) nulliparous and non-pregnant: yes
- Age at study initiation: 7 to 8 weeks
- Weight at study initiation: 201-247 g for males and 192-208 g for females
- Housing:
From arrival to pairing: 5 animals per sex per cage, polysulfone solid bottomed cages. Nesting material was provided and changed at least twice a week.
During mating: 1 male/female pair in clear polysulfone cages with a stainless steel mesh lid and floor. Absorbent material was provided and changed daily.
After mating: Males returned to pre-pairing housing. Females were transferred to individual solid bottomed cages for the gestation period, birth and lactation. Nesting material was provided and changed at least twice a week.
- Diet: ad libitum
- Water: ad libitum
- Acclimation period: 2 weeks for main groups and 3 weeks for recovery groups

ENVIRONMENTAL CONDITIONS
- Temperature (°C): 22±2
- Humidity (%): 55±15
- Air changes (per hr):15-20
- Photoperiod (hrs dark / hrs light): 12/12

IN-LIFE DATES: From experimental start date: 22 December 2016 To: 23 February 2017

Route of administration:
oral: feed
Vehicle:
unchanged (no vehicle)
Details on exposure:
PREPARATION OF DOSING SOLUTIONS:
The test item was formulated daily, using powdered diet, by initial preparation of a premix followed by dilution with further quantities of diet and mixing, at fixed concentrations of 1000, 3000 and 10000 ppm (nominal doses: 100, 300 and 1000 mg/kg bw/day). The formulations were prepared separately for each group. Concentrations were calculated and expressed in terms of test item as supplied.

DIET PREPARATION
- Rate of preparation of diet (frequency): daily
- Mixing appropriate amounts with (Type of food): Powdered rodent diet [4RF21Mucedola s.r.l, SettimoMilanese (MI), Italy].
Details on mating procedure:
- M/F ratio per cage: 1/1
- Length of cohabitation: until positive identification of copulation or at maximum 14 days
- Proof of pregnancy: vaginal plug or sperm in vaginal smear referred to as day 0 of pregnancy
- Further matings after two unsuccessful attempts: no
- After successful mating each pregnant female was caged (how): Females were transferred to individual solid bottomed cages for the gestation period, birth and lactation. Nesting material was provided and changed at least twice a week.
Analytical verification of doses or concentrations:
yes
Details on analytical verification of doses or concentrations:
The proposed formulation was verified from 1000 to 10000 ppm by chemical analysis (concentration and homogeneity) during the pre-treatment, and during the diet preparation of the main study (first and last week of treatment) period. Stability after 28 hours at room temperature was also verified. Results of all analyses were within the acceptability limits (80-120% for concentration and CV<10% for homogeneity).
Duration of treatment / exposure:
Males: 2 consecutive weeks before pairing, during pairing and followed by 2 consecutive weeks up to the day of necropsy.
Females: 2 consecutive weeks prior to pairing and thereafter during pairing, post coitum and post partum periods up until Day 4 post partum (the day of sacrifice)
Recovery groups: Animals had access to their appropriate diets (treated or control diet) depending on treatment group for 4 consecutive weeks. Untreated diet was given during the recovery period.
Frequency of treatment:
Daily
Details on study schedule:
- Age at mating of the mated animals in the study: 9-10 weeks
Dose / conc.:
0 ppm
Remarks:
Included in both main and recovery group
Dose / conc.:
1 000 ppm
Remarks:
Intended dose level: 100 mg/kg bw/day
Dose / conc.:
3 000 ppm
Remarks:
Intended dose level: 300 mg/kg bw/day
Dose / conc.:
10 000 ppm
Remarks:
Intended dose level: 1000 mg/kg bw/day / Included in both main and recovery group
No. of animals per sex per dose:
10 in the main groups
5 in the recovery groups
Control animals:
yes, plain diet
Details on study design:
- Dose selection rationale: Nominal dose levels were selected in agreement with the sponsor, based on a previous preliminary, non GLP compliant study.
- Rationale for animal assignment (if not random): The rats were allocated to the groups by computerised stratified randomisation to give approximately equal initial group mean body weights.
- Post-exposure recovery period: 2 weeks
Positive control:
Not included
Parental animals: Observations and examinations:
CAGE SIDE OBSERVATIONS: Yes
- Time schedule: Once daily during the study, each animal was observed and any clinical signs recorded. Animals were checked for mortality early in the day and in the afternoon.

DETAILED CLINICAL OBSERVATIONS: Yes
- Time schedule: Once before commencement of treatment and at least once a week thereafter, each animal was given a detailed clinical examination.

BODY WEIGHT: Yes
- Time schedule for examinations:
Males: Weighed weekly from allocation to termination
Females: Were weighed weekly from allocation to positive identification of mating and on days 0, 7, 14 and 20 post coitum. Dams were also weighed on Days 1 and 4 post partum.
Recovery: Each animal was weighed on the day of allocation to treatment groups, on the day that treatment commenced, weekly thereafter and just prior to necropsy.

FOOD CONSUMPTION AND COMPOUND INTAKE (if feeding study): Yes
- Food consumption for each animal determined and mean daily diet consumption calculated as g food/kg body weight/day: Yes
- Compound intake calculated as time-weighted averages from the consumption and body weight gain data: Yes

FOOD EFFICIENCY: Yes
- Body weight gain in kg/food consumption in kg per unit time X 100 calculated as time-weighted averages from the consumption and body weight gain data: No

OPHTHALMOSCOPIC EXAMINATION: No

HAEMATOLOGY: Yes
- Time schedule for collection of blood:
as a part of the sacrificial procedure, and at the end of the recovery period.
- Anaesthetic used for blood collection: Yes (isofluorane)
- Animals fasted: Yes
- How many animals:
5 males and 5 females
- Parameters examined:
Haematocrit, Haemoglobin, Red blood cell count, Reticulocyte count, Mean red blood cell volume, Mean corpuscular haemoglobin, Mean corpuscular haemoglobin concentration, White blood cell count, Differential leucocyte count - Neutrophils - Lymphocytes - Eosinophils - Basophils - Monocytes - Large unstained cells, Platelets, Prothrombin time, Coagulation, Activated partial thromboplastin time.

CLINICAL CHEMISTRY: Yes
- Time schedule for collection of blood:
as a part of the sacrificial procedure, and at the end of the recovery period.
- Animals fasted: Yes
- How many animals:
5 males and 5 females
- Parameters examined:
Alkaline phosphatase, Alanine aminotransferase, Aspartate aminotransferase, Gamma-glutamyltransferase, Urea, Creatinine, Glucose, Triglycerides, Bile acids, Inorganic phosphorus, Total bilirubin, Total cholesterol, Total protein, Albumin, Globulin, A/G Ratio, Sodium, Potassium, Calcium, Chloride.

URINALYSIS: Yes (in 5 males/group randomly selected)
- Time schedule for collection of urine: as a part of the sacrificial procedure, and at the end of the recovery period.
- Metabolism cages used for collection of urine: Not specified
- Animals fasted: Yes
- Parameters examined: Appearance, Volume, Specific gravity, pH, Protein, Glucose, Ketones, Bilirubin, Urobilinogen, Blood, Epithelial cells, Leucocytes, Erythrocytes, Crystals, Spermatozoa and precursors, Other abnormal components.

NEUROBEHAVIOURAL EXAMINATION: Yes
- Time schedule for examinations:
once before commencement of treatment and at least once a week thereafter.
- Dose groups that were examined: all
- Battery of functions tested: sensory activity, grip strength andmotor activity
Oestrous cyclicity (parental animals):
Vaginal smears and oestrus cycle
Sperm parameters (parental animals):
The identification of the stages of the spermatogenic cycle was performed in five randomly selected males of the control and high dose groups.
Litter observations:
STANDARDISATION OF LITTERS
- Performed on day 4 postpartum: no

PARAMETERS EXAMINED
The following parameters were examined in F1 offspring: number and sex of pups, stillbirths, live births, postnatal mortality, presence of gross anomalies

GROSS EXAMINATION OF DEAD PUPS
Yes, for external and internal abnormalities; possible cause of death was determined for pups born or found dead.
Postmortem examinations (parental animals):
SACRIFICE
- Male animals: The males were killed after the mating of all females, after a total of 32 or 33 days of dosing.
- Maternal animals: The females with live pups were killed on Day 4 post partum.

GROSS NECROPSY
- Gross necropsy consisted of external and internal examinations including the cervical, thoracic, and abdominal viscera.

HISTOPATHOLOGY / ORGAN WEIGHTS
The tissues indicated ibelow were prepared for microscopic examination and weighed, respectively.
Adrenal glands
Bone marrow (from sternum)
Brain (cerebrum, cerebellum, medulla/pons)
Caecum
Clitoris
Colon
Duodenum
Epididymides
Heart
Ileum
Jejunum (including Peyer’s patches)
Kidneys
Liver
Lungs (including mainstem bronchi)
Lymph nodes – cervical
Lymph nodes – mesenteric
Mammary area
Nasal cavity*
Oesophagus*
Ovaries with Oviducts
Parathyroid glands
Pituitary gland
Penis
Prostate gland
Rectum
Sciatic nerve
Seminal vesicles with coagulation glands
Spinal column*
Spinal cord (cervical, thoracic, lumbar)
Spleen
Stomach
Testes
Thymus (where present)
Thyroid
Trachea
Urinary bladder
Uterus – cervix
Vagina
*Not examined histologically since no signs of toxicity or target organ involvement were noted
Postmortem examinations (offspring):
SACRIFICE
- The F1 offspring were sacrificed at 4 days of age.
- These animals were subjected to postmortem examinations (macroscopic and/or microscopic examination):
All pups found dead in the cage or sacrificed for humane reasons were examined for external and internal abnormalities.
All live pups at termination were killed and examined for external abnormalities and sex confirmation by gonadal inspection.

GROSS NECROPSY
- Gross necropsy consisted of external and internal examinations.
Statistics:
Standard deviations were calculated as appropriate. The criterion for statistical significance was p<0.05.
- Continuous variables: Dunnett’s test or a modified t test, depending on the homogeneity of data.
- Histopathological findings: non-parametric Kolmogorov-Smirnov test if n was more than 5.
- Other parameters: non-parametric Kruskal-Wallis analysis of variance.
- Intergroup differences between the control and treated groups: non-parametric version of the Williams test.
Reproductive indices:
Oestrous cycle and reproductive parameters (pre-coital intervals, copulatory and fertility indices) were measured in treated and control groups.

Males
Copulatory Index (%) = no. of animals mated*100 / no. of animals paired
Fertility Index (%) = no. of males which induced pregnancy*100 / no. of males paired

Females
Copulatory Index (%) = no. of animals mated*100 / no. of animals paired
Fertility Index (%) = no. of pregnant females*100 / no. of females paired
Pre coital Interval = Mean number of days between pairing and mating
Offspring viability indices:
Pre-implantation loss
Pre-birth loss
Post-natal loss
Cumulative pup loss
Clinical signs:
no effects observed
Mortality:
mortality observed, non-treatment-related
Description (incidence):
One female animal and its litter of the low dose group were sacrificed on Day 1 post partum because of prolapse of the left horn of the uterus.
Body weight and weight changes:
no effects observed
Food consumption and compound intake (if feeding study):
effects observed, treatment-related
Description (incidence and severity):
Food consumption:
- Males (all groups): comparable with the control group.
- Females (high dose 1000 mg/kg bw/day nominal): moderately reduced in the first days of dosing and during pre-mating and gestation.
- Females (medium and low dose 100 and 300 mg/kg bw/day nominal): slight decrease
- During the post partum period, food consumption was slightly reduced in all treated groups.
- During the recovery period, the fluctuations in food intake were considered normal and comparable with the control group.
The mean achieved dosages for the dosing period were found to be slightly lower than theoretical dose levels of 1000, 3000 and 10000 ppm. This discrepancy was due to a lower than expected food consumption. The achieved dosages in mg/kg bw/day, for each group, are presented in the attached tables.
Food efficiency:
not specified
Ophthalmological findings:
not examined
Haematological findings:
no effects observed
Clinical biochemistry findings:
effects observed, treatment-related
Description (incidence and severity):
Main study
Statistically significant fluctuations in some biochemical parameters were recorded generally in all treated groups of males and in the high dose group of females. Due to the low severity and/or the absence of dose-relation, the below findings were considered of no toxicological significance, however additional investigations were performed in the recovery phase.

Males
- decrease of potassium in males dosed at 1000 and 3000 ppm (9% and 8%, respectively)
- decrease of creatinine in males dosed at 3000 ppm (25%)
- increase of globulin in males receiving 3000 and 10000 ppm (10% and 15%, respectively)
- increase of phosphorus in those treated at 10000 ppm (23%)

Females
- triglycerides were increased in 2 females dosed at 3000 ppm and one female receiving 10000 ppm. (3.0 to 4.1 fold)
- decrease of aspartate aminotransferase in females dosed at 10000 ppm (39%)
- decrease of creatinine in females dosed at 10000 ppm (13%)
- increase in bile acids in 2 females treated at 10000 ppm (2.2 and 3.7 fold)

Recovery phase
Creatinine was lower than controls in treated males (23%), these changes were considered to be of no toxicological importance, as values were higher when compared to the dosing phase. The other statistically significant differences between control and treated animals (urea and potassium in males) were not observed during the dosing phase, therefore they were considered unrelated to treatment.
Urinalysis findings:
no effects observed
Behaviour (functional findings):
no effects observed
Immunological findings:
not examined
Organ weight findings including organ / body weight ratios:
effects observed, treatment-related
Histopathological findings: non-neoplastic:
effects observed, non-treatment-related
Description (incidence and severity):
Sporadic lesions were reported in control and treated animals in main and recovery phase. These effects were considered to be an expression of spontaneous/or incidental pathology or physiological changes, seen in this species and age in this kind of studies and in our experimental conditions.
Histopathological findings: neoplastic:
effects observed, non-treatment-related
Description (incidence and severity):
An adenocarcinoma was found in the mammary gland of a single treated female. This was considered to be an expression of spontaneous/or incidental pathology and non treatment related.
Reproductive function: oestrous cycle:
no effects observed
Reproductive function: sperm measures:
no effects observed
Reproductive performance:
effects observed, treatment-related
Description (incidence and severity):
Oestrous cycle and reproductive parameters (pre-coital intervals, copulatory and fertility indices) were similar in treated and control groups.
However, a decrease in live litter size at birth and on Days 1 and 4 post partum were observed in mid and high dose group females:
- Mid dose: at birth (-24%) and on Days 1 and 4 post partum (-27% and -28%, respectively)
- High dose: at birth (-15%) and on Days 1 and 4 post partum (-16% and -17%, respectively)
Also a statistically significant reduction in total litter size at birth was noted in the mid- and high groups (-24% and -15%, respectively). In the same dose groups, decrease in corpora lutea and implantation sites (-20% and -13% in the mid- and high dose levels for both parameters) were noted with no statistical significance.
Key result
Dose descriptor:
NOAEL
Effect level:
> 708 mg/kg bw/day (actual dose received)
Based on:
test mat.
Sex:
male
Basis for effect level:
other: highest dose tested
Key result
Dose descriptor:
NOAEL
Effect level:
88 mg/kg bw/day (actual dose received)
Based on:
test mat.
Sex:
female
Basis for effect level:
reproductive performance
Key result
Critical effects observed:
yes
Lowest effective dose / conc.:
249 mg/kg bw/day (actual dose received)
System:
female reproductive system
Organ:
not specified
Treatment related:
yes
Dose response relationship:
not specified
Relevant for humans:
yes
Clinical signs:
effects observed, non-treatment-related
Description (incidence and severity):
The main clinical signs noted In both control and treated groups pups were: cold to the touch, no apparent food intake (milk), small and pale appearance. As the signs were observed in both groups, the were not considered treatment related.
Mortality / viability:
mortality observed, treatment-related
Description (incidence and severity):
A decrease in live litter size at birth and on Days 1 and 4 post partum were observed in mid and high dose group.
- Mid dose: at birth (-24%) and on Days 1 and 4 post partum (-27% and -28%, respectively)
- High dose: at birth (-15%) and on Days 1 and 4 post partum (-16% and -17%, respectively)
Body weight and weight changes:
no effects observed
Description (incidence and severity):
A decrease in absolute litter weight on Days 1 and 4 post partum was observed. However, the decrease in litter weights resulted from the small litter size observed in these groups.
The mean pup weight was similar between control and treated groups both on Days 1 and 4 postpartum.
Food consumption and compound intake (if feeding study):
not examined
Food efficiency:
not examined
Ophthalmological findings:
not examined
Haematological findings:
not examined
Clinical biochemistry findings:
not examined
Urinalysis findings:
not examined
Sexual maturation:
not examined
Organ weight findings including organ / body weight ratios:
not examined
Gross pathological findings:
effects observed, non-treatment-related
Description (incidence and severity):
During lactation period (control and treated groups)
- Autolysis of all organs or of abdominal/thoracic organs
- No milk in stomach

Day 4 (control and treated groups)
- No milk in stomach
Histopathological findings:
not examined
Behaviour (functional findings):
not examined
Developmental immunotoxicity:
not examined
Key result
Dose descriptor:
NOAEL
Generation:
F1
Effect level:
708 mg/kg bw/day (actual dose received)
Based on:
test mat.
Remarks:
Parental exposure
Sex:
male
Basis for effect level:
other: Highest dose tested
Key result
Dose descriptor:
NOAEL
Generation:
F1
Effect level:
88 mg/kg bw/day (actual dose received)
Based on:
test mat.
Remarks:
parental exposure
Sex:
female
Basis for effect level:
viability
Key result
Critical effects observed:
yes
Lowest effective dose / conc.:
249 mg/kg bw/day (nominal)
System:
other: litter size
Organ:
not specified
Treatment related:
yes
Dose response relationship:
not specified
Relevant for humans:
yes
Key result
Reproductive effects observed:
yes
Lowest effective dose / conc.:
88 mg/kg bw/day (actual dose received)
Treatment related:
yes
Relation to other toxic effects:
reproductive effects in the absence of other toxic effects
Dose response relationship:
not specified
Relevant for humans:
yes
Conclusions:
Under the conditions of this study, the NOAEL for reproductive and developmental toxicity was considered to be 708 mg/kg bw/day for males and 88 mg/kg bw/day for females due to a reduced litter size (achieved doses).
Executive summary:

The toxic effects on Sprague Dawley rats after oral repeated dosing (feeding study) with Citronella oil (Cymbopogon winterianus), was investigated according to OECD TG 422, under GLP. The experiment was performed with 10 rats per dose per sex, including a 2 week recovery period. The tested dietary doses corresponded to 1000, 3000 and 10000 ppm (nominal doses: 100, 300 and 1000 mg/kg bw/day). Males were fed with medicated diet for 2 weeks prior to pairing, during pairing with females and until necropsy, for a total of 28 days. Animals of the recovery groups were treated for a total of 4 consecutive weeks and sacrificed after 2 weeks of recovery. Females were fed with medicated diet for 2 weeks prior to pairing, during pairing and throughout the gestation and lactation periods until day 3 post-partum, for at least 41 days. The following parameters were evaluated: mortality, clinical signs (including neurotoxicity assessment, motor activity, grip strength and sensory reaction to stimuli), body weight, food consumption, oestrous cycle, clinical pathology investigations (haematology and clinical chemistry), litter data, macroscopic observations, organ weights and histopathological examination. The identification of the stages of the spermatogenic cycle was performed in five randomly selected males of the control and high dose groups.

 

During the in vivo phase of the study, no relevant clinical signs, neurotoxic or behavioural signs were observed in any treated main animals of both sexes. Body weight as well as body weight gain of treated males did not show differences of toxicological significance throughout the study. Body weight of females did not show differences of toxicological significance (prior to pairing). The food consumption, in male animals of all groups, was generally comparable with the control group. The food consumption, in female animals was moderately reduced in the first days of dosing in the high dose group while a slight decrease was noted in the other two treatment groups. The food consumption normalised during the recovery period. No adverse findings were recorded in clinical pathology investigations. No toxicological relevance was attributed to an observed slight reduction noted in terminal body weight of treated males and females. The variations in organ weights noted were considered unrelated to treatment since they were not associated with histopathological findings. No treatment-related macroscopic and microscopic changes were noted. Reproductive effects were observed in the litters of the mid and high dose groups. A significant decrease in live litter size at birth and on Days 1 and 4 post were observed in the mid and high dose group, when compared to control group. Based on these results, the NOAEL for reproductive and developmental toxicity was considered to be 708 mg/kg bw/day for males and 88 mg/kg bw/day for females (achieved doses).

Effect on fertility: via oral route
Endpoint conclusion:
adverse effect observed
Dose descriptor:
NOAEL
88 mg/kg bw/day
Study duration:
subacute
Species:
rat
Quality of whole database:
Well documented guideline study performed in accordance with GLP conditions.
Additional information

The toxic effects on Sprague Dawley rats after oral repeated dosing (feeding study) with Citronella oil (Cymbopogon winterianus), was investigated according to OECD TG 422, under GLP. The experiment was performed with 10 rats per dose per sex, including a 2 week recovery period. The tested dietary doses corresponded to 1000, 3000 and 10000 ppm (nominal doses: 100, 300 and 1000 mg/kg bw/day). Males were fed with medicated diet for 2 weeks prior to pairing, during pairing with females and until necropsy, for a total of 28 days. Animals of the recovery groups were treated for a total of 4 consecutive weeks and sacrificed after 2 weeks of recovery. Females were fed with medicated diet for 2 weeks prior to pairing, during pairing and throughout the gestation and lactation periods until day 3 post-partum, for at least 41 days. The following parameters were evaluated: mortality, clinical signs (including neurotoxicity assessment, motor activity, grip strength and sensory reaction to stimuli), body weight, food consumption, oestrous cycle, clinical pathology investigations (haematology and clinical chemistry), litter data, macroscopic observations, organ weights and histopathological examination. The identification of the stages of the spermatogenic cycle was performed in five randomly selected males of the control and high dose groups.

 

During the in vivo phase of the study, no relevant clinical signs, neurotoxic or behavioural signs were observed in any treated main animals of both sexes. Body weight as well as body weight gain of treated males did not show differences of toxicological significance throughout the study. Body weight of females did not show differences of toxicological significance (prior to pairing). The food consumption, in male animals of all groups, was generally comparable with the control group. The food consumption, in female animals was moderately reduced in the first days of dosing in the high dose group while a slight decrease was noted in the other two treatment groups. The food consumption normalised during the recovery period. No adverse findings were recorded in clinical pathology investigations. No toxicological relevance was attributed to an observed slight reduction noted in terminal body weight of treated males and females. The variations in organ weights noted were considered unrelated to treatment since they were not associated with histopathological findings. No treatment-related macroscopic and microscopic changes were noted. Reproductive effects were observed in the litters of the mid and high dose groups. A significant decrease in live litter size at birth and on Days 1 and 4 post were observed in the mid and high dose group, when compared to control group. Based on these results, the NOAEL for reproductive and developmental toxicity was considered to be 708 mg/kg bw/day for males and 88 mg/kg bw/day for females (achieved doses).

Justification for classification or non-classification

Based on the available data, the substance does not need to be classified for reproduction toxicity in accordance with the guidance values and criteria outlined in Annex I of the CLP Regulation (1272/2008/EC).

Additional information